Persistent Immunity From Historic Smallpox Vaccination and Its Limited Cross-Neutralization of Monkeypox Virus: A Population-based Serological Study in Taiwan - Scorecard - MDSpire
Advertisement
Persistent Immunity From Historic Smallpox Vaccination and Its Limited Cross-Neutralization of Monkeypox Virus: A Population-based Serological Study in Taiwan
Clinical Scorecard: Long-lasting Immunity from Previous Smallpox Vaccination and Its Limited Effectiveness Against Monkeypox Virus: A Serological Analysis in a Taiwanese Population
At a Glance
Category
Detail
Condition
Monkeypox virus (MPXV) infection
Key Mechanisms
Cross-protection via humoral immunity induced by historic smallpox vaccination and MVA-BN vaccination; assessment of vaccinia virus (VACV)- and MPXV-specific antibody seropositivity and neutralizing capacity
Target Population
Taiwanese individuals stratified by birth year (pre- and post-1979 smallpox vaccination cessation), including MVA-BN vaccine recipients
Care Setting
Public health and vaccination programs, clinical immunology laboratories
Key Highlights
Over 80% of individuals born before 1979 retained VACV-reactive antibodies with 84% showing neutralizing activity.
Cross-reactive MPXV antibodies were detected in 69% of VACV-seropositive individuals, but only 65% had MPXV-neutralizing capacity with significantly lower titers than VACV.
MVA-BN vaccination boosted VACV and MPXV antibody levels but MPXV-neutralizing titers remained low, especially in vaccine-naïve individuals.
Guideline-Based Recommendations
Diagnosis
Use ELISA and plaque reduction neutralization tests (PRNT) to assess VACV- and MPXV-specific antibody responses.
Management
Consider historic smallpox vaccination status when evaluating immunity against MPXV.
Administer MVA-BN vaccine to boost orthopoxvirus immunity in high-risk populations.
Monitoring & Follow-up
Monitor antibody levels post-MVA-BN vaccination to evaluate humoral immune response, especially MPXV-neutralizing titers.
Risks
Limited MPXV-neutralizing capacity in individuals without prior smallpox vaccination despite MVA-BN vaccination.
Potential waning immunity over decades necessitates updated vaccination strategies.
Patient & Prescribing Data
Taiwanese individuals born before and after 1979; MVA-BN vaccine recipients including laboratory workers
Historic smallpox vaccination confers long-lasting humoral immunity with partial cross-protection against MPXV; MVA-BN vaccination enhances antibody levels but may have limited MPXV-neutralizing efficacy in vaccine-naïve individuals.
Clinical Best Practices
Stratify patients by smallpox vaccination history to assess risk and immunity status.
Employ serological assays (ELISA and PRNT) for accurate measurement of orthopoxvirus antibody responses.
Prioritize MVA-BN vaccination for high-risk groups, recognizing its limited neutralizing effect against MPXV in vaccine-naïve populations.
Incorporate findings into public health planning to tailor mpox vaccination strategies based on population vaccination history.
